Sepsis-associated renal vasoconstriction: potential targets for future therapy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Sepsis frequently leads to acute kidney injury (AKI) with decreased glomerular filtration rate (GFR) despite preserved cardiac output.
• Renal vasoconstriction, not structural damage, is the primary cause of AKI in sepsis.
• Vasoconstriction is mediated by locally and systemically released factors.

Discussion:

• Elevated plasma endothelin-1 (ET-1) in sepsis correlates with renal dysfunction.
• ET-1 antagonism improves renal perfusion and function in experimental endotoxemia.
• Thromboxane A2 (TXA2) receptor antagonists and synthesis inhibitors preserve GFR and renal vascular tone in sepsis models.
• TXA2 receptor antagonism also blocks potent vasoconstrictors like prostaglandin F2 (PGF2) analogues.
• Sulfidopeptide leukotrienes (LTs), particularly LTC4 and LTD4, contribute to renal vasoconstriction during sepsis.
• Impaired LT elimination and enhanced production during sepsis exacerbate renal vasoconstriction.
• D-4 receptor antagonism ameliorates renal vasoconstriction in experimental sepsis.

Key Insights:

• Endothelin-1, thromboxane A2, and leukotrienes are key mediators of sepsis-induced renal vasoconstriction.
• Experimental evidence supports the efficacy of blocking these mediators in improving renal function.
• These vasoconstrictors represent promising molecular targets for therapeutic intervention in sepsis-associated AKI.

Outlook:

• Further research into the precise roles and interactions of these mediators is warranted.
• Development of targeted therapies against ET-1, TXA2, and LTs holds potential for treating sepsis-induced kidney injury.
• Future interventions may focus on modulating these specific pathways to preserve renal function during sepsis.